Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 17/20 | 0.81 |
| ▸ | GABRP | O00591 | 1/20 | 0.81 |
| ▸ | GABRD | O14764 | 1/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.81 |
| ▸ | PGR | P06401 | 1/20 | 0.81 |
| ▸ | KLK3 | P07288 | 1/20 | 0.81 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.81 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.81 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.81 |
| ▸ | CNR1 | P21554 | 1/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.81 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.81 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.81 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.81 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.81 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.81 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.81 |
| ▸ | GABRE | P78334 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL189993 | 0.92 | ABCG2 (0.85) | ABCG2ARGABRPGABRDNR1I2 | |
| SCHEMBL10020942 | 0.92 | ABCG2 (0.85) | ABCG2ARGABRPGABRDNR1I2 | |
| SCHEMBL30946717 | 0.91 | ABCG2 (0.83) | ABCG2ARGABRPGABRDNR1I2 | |
| SCHEMBL565106 | 0.91 | ABCG2 (0.83) | ABCG2ARGABRPGABRDNR1I2 | |
| SCHEMBL19529497 | 0.90 | AR (0.82) | ABCG2ARGABRPGABRDNR1I2 | |
| SCHEMBL29563592 | 0.90 | AR (0.82) | ABCG2ARGABRPGABRDNR1I2 | |
| Enzalutamide SCHEMBL189749 | 0.89 | AR (1.00) | ABCG2ARGABRPGABRDNR1I2 | |
| SCHEMBL16586423 | 0.89 | ABCG2 (0.81) | ABCG2ARGABRPGABRDNR1I2 | |
| SCHEMBL21788386 | 0.89 | AR (0.87) | ABCG2ARGABRPGABRDNR1I2 | |
| Enzalutamide SCHEMBL29352764 | 0.89 | AR (1.00) | ABCG2ARGABRPGABRDNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262192-A1 | PROGNOSTIC PATHWAYS FOR HIGH RISK SEPSIS PATIENTS | KONINKLIJKE PHILIPS N.V. (NL) | 2025-08-21 | — | — | US | claimed |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | claimed |
| US-20240180906-A1 | Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer | PFIZER INC. (US) | 2024-06-06 | — | — | US | claimed |
| EP-4313034-A1 | COMBINATION OF TALAZOPARIB AND AN ANTI-ANDROGEN FOR THE TREATMENT OF DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | Pfizer Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| EP-4305206-A1 | PROGNOSTIC PATHWAYS FOR HIGH RISK SEPSIS PATIENTS | Koninklijke Philips N.V. (NL) | 2024-01-17 | — | — | EP | claimed |
| US-20240000783-A1 | COMBINATION THERAPY | PFIZER INC. (US) | 2024-01-04 | — | — | US | claimed |
| EP-4196126-A1 | COMBINATION THERAPY | Pfizer Inc. (US) | 2023-06-21 | — | — | EP | claimed |
| WO-2022200982-A1 | COMBINATION OF TALAZOPARIB AND AN ANTI-ANDROGEN FOR THE TREATMENT OF DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | PFIZER INC. (US) | 2022-09-29 | — | — | WO | claimed |
| WO-2022189530-A1 | PROGNOSTIC PATHWAYS FOR HIGH RISK SEPSIS PATIENTS | KONINKLIJKE PHILIPS N.V. (NL) | 2022-09-15 | — | — | WO | claimed |
| US-20260108513-A1 | Combination of Talazoparib and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer | PFIZER (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4633629-A1 | COMBINATION OF TALAZOPARIB AND ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | Pfizer Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250262192-A1 | PROGNOSTIC PATHWAYS FOR HIGH RISK SEPSIS PATIENTS | KONINKLIJKE PHILIPS N.V. (NL) | 2025-08-21 | — | — | US | disclosed |
| EP-4593828-A1 | COMBINATION OF TALAZOPARIB AND ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | Pfizer Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-8524755-B2 | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524755-B2 | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120035231-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC | 2012-02-09 | — | — | US | disclosed |
| EP-2400847-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | Medivation Prostate Therapeutics, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010099238-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010099238-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR5A2, NR3C1 | ABCG2 330/4885AR 5/4885GABRP 1113/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | ABCG2 595/4885AR 3091/4885GABRP 3243/4885 |
| US-20120035231-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | BPHL, PARK7, APP | ABCG2 1388/4885AR 266/4885GABRP 4093/4885 |
| US-20240180906-A1 | Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer | AR, DDR1, DDRGK1 | ABCG2 1771/4885AR 1/4885GABRP 4430/4885 |
| US-20240000783-A1 | COMBINATION THERAPY | CDK4, CCNI, CCNK | ABCG2 3275/4885AR 57/4885GABRP 4679/4885 |
| US-20260108513-A1 | Combination of Talazoparib and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer | AR, GNRHR, LHCGR | ABCG2 1843/4885AR 1/4885GABRP 3948/4885 |
| US-20250262192-A1 | PROGNOSTIC PATHWAYS FOR HIGH RISK SEPSIS PATIENTS | TGFB1, TGFB2, SMAD3 | ABCG2 4811/4885AR 242/4885GABRP 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.